Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids

Abstract Objective The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) for predicting immunotherapy prognosis and efficacy in Non-small cell lung carcino...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Lei, Chengsong Cao, Rui Tang, Yong Liu
Format: Article
Language:English
Published: BMC 2025-04-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14060-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850201382041157632
author Yan Lei
Chengsong Cao
Rui Tang
Yong Liu
author_facet Yan Lei
Chengsong Cao
Rui Tang
Yong Liu
author_sort Yan Lei
collection DOAJ
description Abstract Objective The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) for predicting immunotherapy prognosis and efficacy in Non-small cell lung carcinoma (NSCLC) treated with Immune checkpoint inhibitors (ICIs) and opioids. Methods A total of 78 NSCLC patients received ICIs and opioids were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, and SII/ALB on patients prognosis. Results NLR and PLR had predictive value of efficacy. SII/ALB > 17.79 was an independent risk factor for worse outcomes. Conclusion PLR and SII/ALB have predictive value of efficacy, but NLR was not. SII/ALB > 17.79 suggests a poor prognosis following immunotherapy in NSCLC patients receiving ICIs and opioids.
format Article
id doaj-art-0a97ef93127f402c92aea003a475ab4f
institution OA Journals
issn 1471-2407
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-0a97ef93127f402c92aea003a475ab4f2025-08-20T02:12:02ZengBMCBMC Cancer1471-24072025-04-012511810.1186/s12885-025-14060-9Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioidsYan Lei0Chengsong Cao1Rui Tang2Yong Liu3Department of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical UniversityDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical UniversitySchool of Public Health, Faculty of Medicine, The University of QueenslandDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical UniversityAbstract Objective The study aimed to assess the value of pretreatment peripheral blood neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and systemic immune-inflammation index/albumin ratio (SII/ALB) for predicting immunotherapy prognosis and efficacy in Non-small cell lung carcinoma (NSCLC) treated with Immune checkpoint inhibitors (ICIs) and opioids. Methods A total of 78 NSCLC patients received ICIs and opioids were retrospectively collected. The optimal cut-off values were determined by receiver operating characteristic curves. The univariate and multivariate analysis investigated the effects of NLR, PLR, and SII/ALB on patients prognosis. Results NLR and PLR had predictive value of efficacy. SII/ALB > 17.79 was an independent risk factor for worse outcomes. Conclusion PLR and SII/ALB have predictive value of efficacy, but NLR was not. SII/ALB > 17.79 suggests a poor prognosis following immunotherapy in NSCLC patients receiving ICIs and opioids.https://doi.org/10.1186/s12885-025-14060-9Peripheral blood inflammatory markerImmune checkpoint inhibitorsOpioidsCancer painNon-small cell lung cancerPrognostic value
spellingShingle Yan Lei
Chengsong Cao
Rui Tang
Yong Liu
Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
BMC Cancer
Peripheral blood inflammatory marker
Immune checkpoint inhibitors
Opioids
Cancer pain
Non-small cell lung cancer
Prognostic value
title Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
title_full Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
title_fullStr Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
title_full_unstemmed Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
title_short Peripheral blood inflammatory biomarkers neutrophil/ lymphocyte ratio, platelet/lymphocyte ratio and systemic immune-inflammation index/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids
title_sort peripheral blood inflammatory biomarkers neutrophil lymphocyte ratio platelet lymphocyte ratio and systemic immune inflammation index albumin ratio predict prognosis and efficacy in non small cell lung cancer patients receiving immunotherapy and opioids
topic Peripheral blood inflammatory marker
Immune checkpoint inhibitors
Opioids
Cancer pain
Non-small cell lung cancer
Prognostic value
url https://doi.org/10.1186/s12885-025-14060-9
work_keys_str_mv AT yanlei peripheralbloodinflammatorybiomarkersneutrophillymphocyteratioplateletlymphocyteratioandsystemicimmuneinflammationindexalbuminratiopredictprognosisandefficacyinnonsmallcelllungcancerpatientsreceivingimmunotherapyandopioids
AT chengsongcao peripheralbloodinflammatorybiomarkersneutrophillymphocyteratioplateletlymphocyteratioandsystemicimmuneinflammationindexalbuminratiopredictprognosisandefficacyinnonsmallcelllungcancerpatientsreceivingimmunotherapyandopioids
AT ruitang peripheralbloodinflammatorybiomarkersneutrophillymphocyteratioplateletlymphocyteratioandsystemicimmuneinflammationindexalbuminratiopredictprognosisandefficacyinnonsmallcelllungcancerpatientsreceivingimmunotherapyandopioids
AT yongliu peripheralbloodinflammatorybiomarkersneutrophillymphocyteratioplateletlymphocyteratioandsystemicimmuneinflammationindexalbuminratiopredictprognosisandefficacyinnonsmallcelllungcancerpatientsreceivingimmunotherapyandopioids